Skip to main content

Table 1 Basic TNBC and Her2 positive patient characteristics

From: The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients

  TNBC Her2 positive
# Total 76 (100%) 96 (100%)
Median patient age 54.3 y (range 28 – 83) 54.0 (range 24 – 79)
# Grading 1 1 (1.3%) 0 (0%)
# Grading 2 20 (26.3%) 39 (40.6%)
# Grading 3 54 (71.1%) 56 (58.3%)
# Grading unknown 1 (1.3%) 1 (1.0%)
# Stage 1 17 (22.4%) 17 (17.7%)
# Stage 2 41 (53.9%) 42 (43.8%)
# Stage 3 9 (11.8%) 22 (22.9%)
# Stage 4 4 (5.3%) 13 (13.5%)
# Staging unknown 5 (6.6%) 2 (2.1%)
pNO (initial diagnosis) 41 (53.9%) 33 (34.3%)
pN+ 29 (38.2%) 58 (60.4%)
pNX 6 (7.9%) 5 (5.2%)
Metastatic patients (initial diagnosis) 14 (18.4%) 13 (13.5%)
Median OS [months] 55.8 (range 0.9 – 238) 41.2 (range 13.0 – 193.5)
Median EFS [months] 50.9 (range 0.9 – 197.9) 33.3 (range 7.8 – 114)